Adma Biologics Inc (ADMA) — Smart Money Tracker (13F, Q2 2026)

ADMA ranks #1942 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

ADMA is a top-conviction position for B Group, Inc. — at 12.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ADMA belongs to BlackRock, Inc., but the position matters far more to B Group, Inc., who has 12.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Essential Partners LLC has added to its ADMA position for two straight quarters, increasing it by $5.3K to reach $5.7K today.

Y-Intercept has trimmed its ADMA position for two straight quarters, cutting it by $8.2M while still holding $1.5M.

ADMA is down 0.5% today, and institutions have been net sellers of $9.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ADMA posted net income of $169.0M over the trailing twelve months, and currently trades at a P/E of 15.5.

• Profitable — net income of $169.0M over the trailing twelve months
• Revenue grew 8.0% year over year
• Net income declined year over year, from $208.9M to $169.0M
• Generated $50.4M in positive operating cash flow
• Current ratio of 6.71x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.31x equity — within a conventional range